Fact sheet comparisons
Compare the evidence side by side.
Compare related compounds by approved uses, human research, risks and open questions. You can also select any three fact sheets in the library.
GLP-1 peptides compared
How semaglutide, tirzepatide, liraglutide, and investigational retatrutide differ in targets, evidence, and approval status.
Peptides for weight management: approved versus experimental
A status-first look at approved medicines and experimental peptides discussed for body weight.
Peptides for recovery: what evidence exists?
What the evidence says about BPC-157, thymosin beta-4, CJC-1295, and ipamorelin for injury recovery.
Peptides for skin and aging: research versus hype
Evidence for cosmetic peptides and systemic aging claims.
Growth hormone pathway peptides compared
How tesamorelin, sermorelin, CJC-1295, and ipamorelin differ in mechanism, status, and evidence.
Mitochondrial peptides compared
How FDA-approved elamipretide differs from preclinical MOTS-c and Humanin research in status, evidence, muscle claims, and healthy-aging hype.
Peptides for cognition and brain research: evidence versus nootropic claims
A status-first comparison of Semax, Selank, oxytocin, and Humanin for cognition, social functioning, anxiety, and neuroprotection.
Peptides for muscle growth and performance: what human evidence shows
Why growth-hormone signals, mitochondrial biology, and body-composition claims do not automatically prove more muscle, strength, recovery, or performance.
Next-generation metabolic peptides: beyond GLP-1 alone
How amylin analogs and glucagon-containing co-agonists differ in targets, trial maturity, liver research, weight evidence, and FDA status.
Gut-signaling peptide medicines compared
Why linaclotide, plecanatide, and teduglutide are all gut-related peptides but are not interchangeable treatments or evidence for general gut repair.
GLP-1 peptides in Parkinson research
What the positive LIXIPARK trial and negative exenatide Phase 3 study say about GLP-1 neuroprotection claims.